A new institute which aims to develop new treatments, which will change the practice of ophthalmology, has been officially launched this week at the biennial World Ophthalmology Congress.
The Institute of Molecular and Clinical Ophthalmology Basel (IOB), Switzerland, will see researchers and clinicians work together to advance the understanding of eye diseases and to develop new therapies for vision loss.The research institute will establish 10 endowed professorships and 125 additional positions for scientists by 2024.
“Our goal is to change the field of ophthalmic therapy. We are working to accelerate the conversion of basic research into innovative treatments, and to turn discoveries and technologies into clinical applications for blinding conditions,” said Professor Hendrik Scholl from the University of Basel (UB) who, together with Professor Botond Roska, also from UB will lead the organisation.
“At IOB, our basic researchers and clinicians work hand in hand daily to improve the understanding of vision, and of the mechanisms involved in eye disease. Together we develop new treatments which change the practice of ophthalmology, based on the genetic, structural and functional understanding of the cell types and their interactions within the human eye,” added Professor Roska.